| IRWD Stock Down 15% as Q1 Earnings & Revenues Miss Estimates |
Ironwood incurs a wider-than-expected loss in the first quarter of 2025. Revenues plunge year over year. |
zacks.com |
2025-05-08 14:55:45 |
Czytaj oryginał (ang.) |
| Ironwood Pharmaceuticals (IRWD) Reports Q1 Loss, Misses Revenue Estimates |
Ironwood Pharmaceuticals (IRWD) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.02 per share a year ago. |
zacks.com |
2025-05-07 13:20:41 |
Czytaj oryginał (ang.) |
| Ironwood Pharmaceuticals Reports First Quarter 2025 Results |
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its first quarter 2025 results and recent business performance. “LINZESS demand continues to be strong, and we remain on track to meet our full-year 2025 guidance and further, recently raised our adjusted EBITDA guidance. We are making a concerted effort to maximize st. |
businesswire.com |
2025-05-07 11:05:00 |
Czytaj oryginał (ang.) |
| Analysts Estimate Ironwood Pharmaceuticals (IRWD) to Report a Decline in Earnings: What to Look Out for |
Ironwood (IRWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-05-01 15:07:13 |
Czytaj oryginał (ang.) |
| Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference |
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that management will participate in a fireside chat at The Citizens Life Sciences Conference on Wednesday, May 7th at 12:00 p.m. ET at the New York Hilton Midtown. A live webcast of Ironwood's fireside chat will be accessible through the Investors section of the company's website at www.ironwoodpharma.com. A replay of the webcast will be available on Ironwood's website following the conference. About Ironwood. |
businesswire.com |
2025-04-30 20:25:00 |
Czytaj oryginał (ang.) |
| Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance |
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced it reiterates its full year 2025 LINZESS U.S. net sales and total Ironwood revenue guidance and raises its adjusted EBITDA guidance. Ironwood plans to report full first quarter 2025 results in early May. “Today, we are reiterating our full-year 2025 LINZESS U.S. net s. |
businesswire.com |
2025-04-25 11:05:00 |
Czytaj oryginał (ang.) |
| Ironwood Pharmaceuticals to Present Real-World Data at Digestive Disease Week® 2025 on Adoption of New Diagnosis Codes Among Short Bowel Syndrome Patients Who Are Dependent on Parenteral Support |
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, announced today that the company will present real-world data during the 2025 Digestive Disease Week® (DDW) meeting, taking place May 3-6 in San Diego, CA. These data will focus on the adoption and utilization of recently approved ICD-10 (International Statistical Classification of Di. |
businesswire.com |
2025-04-22 20:05:00 |
Czytaj oryginał (ang.) |
| Ironwood Shares Tank on Regulatory Update for Apraglutide |
Per the latest discussion with the FDA, a confirmatory phase III study is required to seek approval for IRWD's apraglutide in short bowel syndrome with intestinal failure. |
zacks.com |
2025-04-15 14:20:30 |
Czytaj oryginał (ang.) |
| Ironwood Pharmaceuticals Stock Plunges, FDA Wants Another Trial For Gastrointestinal Drug |
Ironwood Pharmaceuticals, Inc. IRWD on Monday announced that the U.S. Food and Drug Administration (FDA) wants a confirmatory Phase 3 trial to approve apraglutide for short bowel syndrome with intestinal failure. |
benzinga.com |
2025-04-14 18:19:35 |
Czytaj oryginał (ang.) |
| Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide |
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced that, based on a recent discussion with the U.S. Food and Drug Administration (FDA), a confirmatory Phase 3 trial is needed to seek approval of apraglutide for patients with short bowel syndrome (SBS) with intestinal failure (IF) who are dependent on parenteral suppor. |
businesswire.com |
2025-04-14 11:00:00 |
Czytaj oryginał (ang.) |
| Ironwood Pharmaceuticals: Setting A Strong Foundation For A Return To Growth |
Ironwood Pharmaceuticals (IRWD) is undergoing a challenging transition with LINZESS but has promising growth potential with apraglutide for short bowel syndrome (SBS). Despite declining revenue, LINZESS remains the market leader, and Ironwood's restructuring efforts aim to streamline operations and focus on apraglutide. Apraglutide's strong clinical data and potential FDA approval could significantly boost Ironwood's revenue, positioning it as a key player in the SBS market. |
seekingalpha.com |
2025-04-10 14:49:40 |
Czytaj oryginał (ang.) |
| Google launches new Ironwood chip to speed AI applications |
Alphabet's on Wednesday unveiled its seventh-generation artificial intelligence chip named Ironwood, which the company said is designed to speed the performance of AI applications. |
reuters.com |
2025-04-09 12:12:24 |
Czytaj oryginał (ang.) |
| Ironwood Pharmaceuticals Announces Receipt of Nasdaq Non-Compliance Notification Regarding Late 2024 Form 10-K Filing |
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (the “Company”) (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced that it received a notification letter (the “Notice”) on March 21, 2025 from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of the Company's delay in filing its Annual Report on Form 10-K fo. |
businesswire.com |
2025-03-27 18:05:00 |
Czytaj oryginał (ang.) |
| Industry Veteran Launches Ironwood III With Substantial Equity Commitment From Kayne Anderson Energy Infrastructure Fund |
SAN ANTONIO--(BUSINESS WIRE)--Ironwood Midstream Energy Partners III, LLC (Ironwood III) today announced it has secured a substantial equity commitment from Kayne Anderson Energy Infrastructure Fund, Inc. (KYN). Led by industry veteran Mike Williams, Ironwood III has a long-term operating strategy, focused on the acquisition, development, and operation of top-tier midstream assets in the most economic and desirable oil and gas producing regions in the United States. In conjunction with the equi. |
businesswire.com |
2025-03-25 10:30:00 |
Czytaj oryginał (ang.) |
| Billionaire Healthcare Investor Alex Denner's Hedge Fund Has 75% of Its Assets in These 3 Stocks |
If you work in the biotech industry, you might know the name Alex Denner. |
247wallst.com |
2025-03-17 17:01:32 |
Czytaj oryginał (ang.) |
| IRWD's Q4 Earnings and Revenues Fall Shy of Estimates, Stock Down |
Ironwood reports weaker-than-expected results for the fourth quarter of 2024. The company maintains total revenue guidance for 2025. |
zacks.com |
2025-02-28 14:46:16 |
Czytaj oryginał (ang.) |
| Ironwood Pharmaceuticals, Inc. (IRWD) Q4 2024 Earnings Call Transcript |
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Greg Martini - Chief Financial Officer Tom McCourt - Chief Executive Officer Mike Shetzline - Chief Medical Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Jason Butler - Citizens JMP Matt Cowper - Leerink Partners David Amsellem - Piper Sandler Operator My name is Kathleen, and I will be your conference operator today. At this time, I would like to welcome everyone to the Ironwood Pharmaceuticals Fourth Quarter 2024 Investor Update Conference Call. |
seekingalpha.com |
2025-02-27 13:21:11 |
Czytaj oryginał (ang.) |
| Ironwood Pharmaceuticals (IRWD) Q4 Earnings and Revenues Miss Estimates |
Ironwood Pharmaceuticals (IRWD) came out with quarterly earnings of $0.02 per share, missing the Zacks Consensus Estimate of $0.10 per share. This compares to break-even earnings per share a year ago. |
zacks.com |
2025-02-27 11:20:34 |
Czytaj oryginał (ang.) |
| Millrose Properties Set to Join S&P SmallCap 600 |
NEW YORK , Feb. 5, 2025 /PRNewswire/ -- Millrose Properties Inc. (NYSE: MRP) will replace Ironwood Pharmaceuticals Inc. (NASD: IRWD) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, February 10. S&P 500 constituent Lennar Corp (NYSE: LEN) is spinning off Millrose Properties in a transaction expected to be completed on Friday, February 7. |
prnewswire.com |
2025-02-05 20:28:00 |
Czytaj oryginał (ang.) |
| IRWD Begins Apraglutide NDA Submission, Announces Job Cuts, Stock Falls |
Ironwood begins the rolling NDA filing for apraglutide to treat short bowel syndrome patients dependent on parenteral support. |
zacks.com |
2025-01-30 14:51:24 |
Czytaj oryginał (ang.) |
| Ozempic is in the next round of Medicare drug price negotiations. See the full list of 15 medications |
The Biden administration unveiled the next 15 prescription drugs that will be subject to price negotiations between manufacturers and Medicare. It kicks off the second phase of a landmark provision in the Inflation Reduction Act that aims to make costly medications more affordable for seniors. |
cnbc.com |
2025-01-17 10:07:46 |
Czytaj oryginał (ang.) |
| Ironwood Pharmaceuticals to Participate in the Piper Sandler 36th Annual Healthcare Conference |
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that management will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024 at 12:30 p.m. ET at the Lotte New York Palace. A live webcast of Ironwood's fireside chat will be accessible through the Investors section of the company's website at www.ironwoodpharma.com. A replay of the webcast will be available on Ironwood's website following the confe. |
businesswire.com |
2024-11-26 18:01:00 |
Czytaj oryginał (ang.) |
| Ironwood Pharmaceuticals to Participate in the Jefferies London Healthcare Conference |
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that Sravan Emany, Chief Operating Officer and Chief Financial Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024 at 7:30 a.m. GT at the Waldorf Hilton in London. A live webcast of Ironwood's fireside chat will be accessible through the Investors section of the company's website at www.ironwoodpharma.com. A replay of the webcast will be a. |
businesswire.com |
2024-11-13 18:01:00 |
Czytaj oryginał (ang.) |
| Ironwood's Q3 Earnings Lag Estimates, Revenues Top, Stock Down |
IRWD's third-quarter earnings miss estimates while revenues beat the same. The company maintains revenue guidance for 2024. |
zacks.com |
2024-11-08 14:06:12 |
Czytaj oryginał (ang.) |
| Ironwood Pharmaceuticals, Inc. (IRWD) Q3 2024 Earnings Call Transcript |
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD ) Q3 2024 Earnings Call Transcript November 7, 2024 8:30 AM ET Company Participants Matt Roache - Director of Investor Relations Tom McCourt - Chief Executive Officer Mike Shetzline - Chief Medical Officer Sravan Emany - Chief Operating Officer & Chief Financial Officer Conference Call Participants Amy Li - Jefferies David Amsellem - Piper Sandler Jason Butler - Citizens JMP Mohit Bansal - Wells Fargo Operator Thank you for standing by. My name is Louella, and I will be your conference operator today. |
seekingalpha.com |
2024-11-08 00:34:01 |
Czytaj oryginał (ang.) |
| Ironwood Pharmaceuticals (IRWD) Misses Q3 Earnings Estimates |
Ironwood Pharmaceuticals (IRWD) came out with quarterly earnings of $0.02 per share, missing the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.12 per share a year ago. |
zacks.com |
2024-11-07 11:21:20 |
Czytaj oryginał (ang.) |
| Once-Weekly Apraglutide Showed Consistent Treatment Effect Across Baseline Demographics and Disease Characteristics in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF), According to New STARS Phase III Data from Ironwood at ACG 2024 |
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, will present new findings at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting and Postgraduate Course from subgroup analyses of the primary endpoint of the pivotal Phase III clinical trial, STARS, evaluating the treatment effect of apraglutide by baseline demographics and disease-specific characteristics in adults with short bowel syndrome with intestinal failure. |
businesswire.com |
2024-10-28 09:00:00 |
Czytaj oryginał (ang.) |
| Ironwood Pharmaceuticals to Host Third Quarter 2024 Investor Update Call |
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its third quarter 2024 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, November 7, 2024. Individuals interested in participating in the call should dial (888) 596-4144 (U.S. and Canada) or (646) 968-2525 (international) using conference ID number and event passcode 2530602. To access the webcast, please visit the Investors section of Ironwood's website at www.ir. |
businesswire.com |
2024-10-24 20:00:00 |
Czytaj oryginał (ang.) |
| Ironwood Pharmaceuticals, Inc. (IRWD) Q2 2024 Earnings Call Transcript |
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD ) Q2 2024 Earnings Conference Call August 8, 2024 8:30 AM ET Company Participants Matt Roache - Director of Investor Relations Tom McCourt - Chief Executive Officer Mike Shetzline - Chief Medical Officer Sravan Emany - Chief Operating Officer & Chief Financial Officer Andrew Davis - Chief Business Officer Conference Call Participants David Amsellem - Piper Sandler Amy Li - Jefferies Mohit Bansal - Wells Fargo Jason Butler - Citizens JMP Tim Chiang - Capital One Operator Thank you for standing by. My name, Celine, and I will be your conference operator today. |
seekingalpha.com |
2024-08-09 16:10:26 |
Czytaj oryginał (ang.) |
| Ironwood (IRWD) Q2 Earnings & Revenues Fall Shy of Estimates |
Ironwood (IRWD) reports breakeven earnings for second-quarter 2024. Revenues miss estimates. |
zacks.com |
2024-08-09 16:00:39 |
Czytaj oryginał (ang.) |
| Ironwood Pharmaceuticals (IRWD) Reports Break-Even Earnings for Q2 |
Ironwood Pharmaceuticals (IRWD) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of $0.17. This compares to earnings of $0.31 per share a year ago. |
zacks.com |
2024-08-08 13:17:12 |
Czytaj oryginał (ang.) |
| Earnings Preview: Ironwood Pharmaceuticals (IRWD) Q2 Earnings Expected to Decline |
Ironwood (IRWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2024-08-01 15:06:00 |
Czytaj oryginał (ang.) |
| New Strong Sell Stocks for July 23rd |
ALK, DINO and IRWD have been added to the Zacks Rank #5 (Strong Sell) List on July 23, 2024. |
zacks.com |
2024-07-23 11:25:29 |
Czytaj oryginał (ang.) |
| New Strong Sell Stocks for July 5th |
ARCO, IRWD and AVT have been added to the Zacks Rank #5 (Strong Sell) List on July 5, 2024. |
zacks.com |
2024-07-05 12:06:32 |
Czytaj oryginał (ang.) |
| The Schall Law Firm Starts Investigation Into Claims Against Ironwood Pharmaceuticals Inc And Encourages Investors With Losses To Begin Conversation |
LOS ANGELES, CA / ACCESSWIRE / June 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ironwood Pharmaceuticals, Inc. ("Ironwood" or "the Company") (NASDAQ:IRWD) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accesswire.com |
2024-06-28 15:00:00 |
Czytaj oryginał (ang.) |
| The Schall Law Firm Initiates Inquiry Into Allegations Against Ironwood Pharmaceuticals Inc And Urges Investors Who Incurred Losses To Initiate Dialogue |
LOS ANGELES, CA / ACCESSWIRE / June 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ironwood Pharmaceuticals, Inc. ("Ironwood" or "the Company") (NASDAQ:IRWD) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accesswire.com |
2024-06-26 19:30:00 |
Czytaj oryginał (ang.) |
| The Schall Law Firm Initiates Probe Into Allegations Against Ironwood Pharmaceuticals Inc And Urges Investors Who Suffered Losses To Initiate Contact |
LOS ANGELES, CA / ACCESSWIRE / June 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ironwood Pharmaceuticals, Inc. ("Ironwood" or "the Company") (NASDAQ:IRWD) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accesswire.com |
2024-06-25 18:45:00 |
Czytaj oryginał (ang.) |
| The Schall Law Firm Begins Investigation Into Claims Against Ironwood Pharmaceuticals Inc And Encourages Investors With Losses To Establish Communication |
LOS ANGELES, CA / ACCESSWIRE / June 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ironwood Pharmaceuticals, Inc. ("Ironwood" or "the Company") (NASDAQ:IRWD) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accesswire.com |
2024-06-24 20:45:00 |
Czytaj oryginał (ang.) |
| The Schall Law Firm Initiates Probe Into Allegations Against Ironwood Pharmaceuticals Inc And Urges Investors With Losses To Connect |
LOS ANGELES, CA / ACCESSWIRE / June 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ironwood Pharmaceuticals, Inc. ("Ironwood" or "the Company") (NASDAQ:IRWD) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accesswire.com |
2024-06-23 15:00:00 |
Czytaj oryginał (ang.) |
| The Schall Law Firm Begins Investigation Into Claims Against Ironwood Pharmaceuticals Inc And Encourages Investors With Losses To Reach Out |
LOS ANGELES, CA / ACCESSWIRE / June 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ironwood Pharmaceuticals, Inc. ("Ironwood" or "the Company") (NASDAQ:IRWD) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accesswire.com |
2024-06-22 15:00:00 |
Czytaj oryginał (ang.) |
| The Schall Law Firm Initiates Probe Into Allegations Against Ironwood Pharmaceuticals Inc And Urges Investors With Losses To Connect |
LOS ANGELES, CA / ACCESSWIRE / June 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ironwood Pharmaceuticals, Inc. ("Ironwood" or "the Company") (NASDAQ:IRWD) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. |
accesswire.com |
2024-06-21 21:00:00 |
Czytaj oryginał (ang.) |